The Indel platform technology has the ability to create a large and growing pipeline of novel antimicrobial drugs. The Company is currently advancing a number of antibacterial programs and one anti-parasitic program internally and is continuing to enhance its antibacterial indel target database, which contains hundreds of attractive indel differentiated targets from a range of clinically and commercially interesting pathogens. Given the breadth of its platform, Indel is interested in establishing strategic relationships to advance its platform and programs to develop novel treatments for serious bacterial, fungal, parasitic and viral infections.
“If the Indel concept works it will be a game changer for the treatment of infectious disease.”
- Infectious Disease Thought Leader Larger Pharmaceutical Company
For inquiries regarding partnering and investment please contact:
Indel’s Business Development Team Tel: (604) 551-8464 Email:bd@indelrx.com
